11th International Symposium on Minimal Residual Cancer

> Final Program

May 3-5, 2018

Le Corum
MONTPELLIER, FRANCE

Organizers:
Catherine Alix-Panabières *(Montpellier, France)*
Klaus Pantel *(Hamburg, Germany)*

www.ismrc2018.com

VISIT BOOTH #14

LIQUID BIOPSY

SEE MORE. SEE CLEARLY.
DROPLET DIGITAL™ PCR



Find out why one technology is transforming liquid biopsy.

Droplet Digital PCR (ddPCR™) has emerged as the clearest path to the clinic for liquid biopsy. Its superior sensitivity and rapid time to results have allowed laboratories to develop tests for monitoring disease, tracking treatment efficacy, and identifying disease recurrence earlier and more confidently than ever before.

Visit bio-rad.com/liquidbiopsy to see how ddPCR Systems are changing the field of liquid biopsy by letting scientists see more.

BIO-RAD

> Welcome to Montpellier

Catherine Alix-Panabières

Klaus Pantel

Dear Colleagues and Friends,

We warmly welcome you to the 11th International Symposium on Minimal Residual Cancer in Montpellier in the south of France.

These international ISMRC meetings started in 1996 and have established themselves, every other year, as a premier event focusing on **Minimal Residual Cancer** in patients with solid tumors.

The MONTPELLIER ISMRC meeting is a great opportunity to gather during three days, researchers from academia and industry to share information about the most recent technical developments, clinical trials and late breaking news.

The 2018 meeting in Montpellier is organized together with the established EU-IMI consortium CANCER-ID and brings together basic and clinical researchers from academia and companies. The MONTPELLIER-ISMRC 2018 program will focus on **LIQUID BIOPSY** in a broader sense and will include presentations on Circulating Tumor Cells (CTCs) as well as circulating nucleic acids (DNA, miRNA) and exosomes, with emphasis on clinical studies as well as the biology of metastasis, including cancer stemness, dormancy, epithelial-mesenchymal transition and immunomodulation of tumor cells.

Besides invited plenary talks by leading international experts, the MONTPELLIER-ISMRC 2018 includes oral communications and poster presentations selected from the submitted abstracts to support young investigators as well as a session for companies developing new technologies for liquid biopsy. We invite you to submit your abstract for consideration by our Advisory Committee for presentation at the MONTPELLIER-ISMRC 2018 meeting.

After great cities like Munich, Berlin, Oslo, San Francisco, Hamburg, Athens, Osaka & Paris, the next ISMRC will take place **May 3-5, 2018 at the Corum in Montpellier, France**. We hope that you will enjoy your time attending this 11th ISMRC meeting in MONTPELLIER and enjoy the opportunity to exchange information and establish long lasting collaborations with your colleagues.

We will be very happy to welcome you in May 2018 in Montpellier!

ion torrent



Identify driver and resistance mutations with one tube of blood

From blood sample to variant data—2 day, end-to-end NGS workflows for liquid biopsy research

FIND OUT MORE AT BOOTH #15

Don't miss relevant mutations—go beyond single-analyte assays and streamline your mutation detection efforts with a single next-generation sequencing (NGS) workflow.

- Detect rare mutations down to a 0.1% frequency with Ion Torrent™ Oncomine™ cfDNA NGS assays
- Streamline multiplex targeted sequencing with Ion S5™ Systems
- Interpret sample-specific variant data matched with relevant labels, guidelines, and clinical trials using the Ion Torrent™ Oncomine™ Knowledgebase Reporter

Visit us at thermofisher.com/liquidbiopsy

ThermoFisher SCIENTIFIC

For Research Use Only. Not for use in diagnostic procedures.
© 2018 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.

> Committee & Speakers

Scientific Committee

Catherine Alix-Panabières *(Montpellier, France)*
Klaus Pantel *(Hamburg, Germany)*
Evi Lianidou *(Athens, Greece)*
Jean-Yves Pierga *(Paris, France)*
Nick Stoecklein *(Düsseldorf, Germany)*
Michael Speicher *(Graz, Austria)*

Confirmed Speakers

Catherine Alix-Panabières *(Montpellier, France)*
Emmanuel Antonarakis *(Baltimore, USA)*
Carlos Caldas *(Cambridge, UK)*
George Calin *(Houston, USA)*
Lewis Chodosh *(Philadelphia, USA)*
Michael Clarke *(Stanford, USA)*
Luis Diaz *(Baltimore, USA)*
Caroline Dive *(Manchester, UK)*
Hugh Fan *(Gainsville, USA)*
Françoise Farace *(Paris, France)*
Thomas Friedl *(Ulm, Germany)*
Jérôme Galon *(Paris, France)*
Renaud Garrel *(Montpellier, France)*
Paola Gazzaniga *(Roma, Italy)*
Christine Gilles *(Lièges, Belgium)*
Daniel Hayes *(Michigan, USA)*
Paul Hofman *(Nice, France)*
Dave Hoon *(Santa Monica, USA)*
Stefanie Jeffrey *(Stanford, USA)*
Raghu Kalluri *(Houston, USA)*
Yibin Kang *(Princetown, USA)*
Evi Lianidou *(Athens, Greece)*
Dennis Lo *(Hong-Kong, China)*
David Lyden *(New-York, USA)*
Dario Marchetti *(Houston, USA)*
Joan Massagué *(New-York, USA)*
Thibaut Mazard *(Montpellier, France)*
Klaus Pantel *(Hamburg, Germany)*
Jean-Yves Pierga *(Paris, France)*
Alain Puisieux *(Lyon, France)*
Howard Scher *(New-York, USA)*
Jonathan Sleeman *(Heidelberg, Germany)*
Michael Speicher *(Graz, Austria)*
Nick Stoecklein *(Duesseldorf, Germany)*
Leon Terstappen *(Twente, The Netherlands)*
Frédéric Thomas *(Montpellier, France)*
Jean-Paul Thiery *(Paris, France)*
Rik Thompson *(Brisbane, Australia)*
Robert Weinberg *(Boston, USA)*
Tom Würdinger *(Amsterdam, The Netherlands)*
Bruce Zetter *(Boston, USA)*

Endorsement

Program Summary

May 3-5, 2018

Le Corum
MONTPELLIER, FRANCE

THURSDAY MAY 3rd, 2018

	AUDITORIUM PASTEUR	LEVEL 3
8h20	**WELCOME REMARKS**	EXHIBITION
8h30	**OPENING**	
9h00	**KEYNOTE LECTURE** Liquid Biopsy: Biology and Clinical Applications	
9h30	**SESSION 1 (I/II)** Cancer Cell Stemness and Epithelial-Mesenchymal Plasticity	
	10h50-11h20 // Coffee Break & Visit of the Exhibition	
11h20	**SESSION 1 (II/II)** Cancer Cell Stemness and Epithelial-Mesenchymal Plasticity	EXHIBITION
	12h35-13h45 // Lunch Break & Visit of the Exhibition	
13h45	**SESSION 2** Evolution & Cancer	EXHIBITION
14h10	**SESSION 3 (I/II)** Immune System and Cancer	
14h35		**SESSION 4** Poster Sessions 14h35 Poster Session 1 15h20 Poster Session 2
	16h05-16h35 // Coffee Break & Visit of the Exhibition	
16h35	**SESSION 5** Selected Oral Presentations	EXHIBITION

FRIDAY MAY 4th, 2018

	AUDITORIUM PASTEUR	LEVEL 3
8h30	**SESSION 6 (I/II)** Biology of Tumor Cell Dissemination and Metastasis	EXHIBITION
	9h50-10h20 // Coffee Break & Visit of the Exhibition	
10h20	**SESSION 6 (II/II)** Biology of Tumor Cell Dissemination and Metastasis	EXHIBITION
11h10	**SESSION 7 (I/II)** Circulating Tumor Cells	
	12h25-13h35 // Lunch Break & Visit of the Exhibition	
13h35	**SESSION 7 (II/II)** Circulating Tumor Cells	EXHIBITION
	15h15-15h45 // Coffee Break & Visit of the Exhibition	
15h45	**SESSION 8** Circulating Cell-Free Tumor DNA and Exosomes	EXHIBITION
20h00	**Gala Dinner**	

SATURDAY MAY 5th, 2018

	AUDITORIUM PASTEUR	LEVEL 3
8h30	**SESSION 9 (I/II)** CTCs as liquid biopsy in Clinical Studies	EXHIBITION
	10h35-11h05 // Coffee Break & Visit of the Exhibition	
11h05	**SESSION 9 (II/II)** CTCs as liquid biopsy in Clinical Studies	EXHIBITION
	13h15-14h25 // Lunch Break & Visit of the Exhibition	
14h25	**SESSION 10** Emerging Commercial Technologies	EXHIBITION
15h15	**SESSION 3 (II/II)** Immune System and Cancer	
	15h40-16h10 // Coffee Break & Visit of the Exhibition	
16h10	**SESSION 11** Circulating Cell-Free miRNA and Platelets	EXHIBITION
17h00	**Closing Remarks with Poster and Travel Awards**	

08h20 **Welcome Remarks**
Catherine Alix-Panabières (France), Pantel K. (Germany)

08h30 **Opening**
Director ITMO & INCa (National Institute of Cancer Research) - *Christine Chomienne*
General Director, CHU Hospital Montpellier - *Thomas Le Ludec*
Dean, Faculty of Medicine, CHU Hospital Montpellier - *Michel Mondain*
President of the University of Montpellier - *Philippe Augé*
Mayor of Montpellier - *Philippe Saurel*
Regional President - *Carole Delga*

9h00 Keynote Lecture: Liquid Biopsy: Biology and Clinical Applications
Klaus Pantel (Germany)

SESSION 1
Cancer cell stemness and epithelial-mesenchymal plasticity
Chairmen: Mani Sendurai (USA), Jean-Paul Thiery (France)

09h30 Keynote Lecture: Role of Epithelial-Mesenchymal Transition in Tumor Progression
Robert Weinberg (USA)

10h00 Epithelial mesenchymal transition in carcinoma; therapeutic intervention
Jean-Paul Thiery (France)

10h25 Epithelial-mesenchymal plasticity in breast cancer model systems; Implications for metastatic progression of clinical breast cancer.
Rik Thompson (Australia)

10h50-11h20 // Coffee Break & Visit of the Exhibition

11h20 Identification of markers for metastatic, drug resistant breast cancer stem cells
Michael Clarke (USA)

11h45 EMT-driven coagulation: impact for Circulating Tumor Cells
Christine Gilles (Belgium)

12h10 ZEB1, an EMT inducer at the crux of stemness, cancer genetics and metastatic dissemination
Alain Puisieux (France)

12h35-13h45 // Lunch Break & Visit of the Exhibition

SESSION 2
Evolution & cancer
Chairman: Jean-Marc Lacorte (France)

13h45 An evolutionary perspective of cancer
Frédéric Thomas (France)

SESSION 3
Immune system and cancer (I/II)
Chairman: Jean-Marc Lacorte (France)

14h10 Monitoring immunotherapies with liquid biopsies
Paola Gazzaniga (Italy)

SESSION 4
Poster sessions

14h35 Poster Session 1 (in the Exhibition area)

15h20 Poster Session 2 (in the Exhibition area)

16h05-16h35 // Coffee Break & Visit of the Exhibition

SESSION 5
Oral communications
Chairpersons: Evi Lianidou (Greece), Nick Stoecklein (Germany)

16h35 Disseminated tumor cells (DTC) of high-risk neuroblastoma patients undergo transcriptional alterations during disease progression – RNA-seq and first steps towards DTC-derived zebrafish xenografts
Rifatbegovic F. (Austria), Taschner-Mandl S. (Austria), Pascoal S. (Austria), Distel M. (Austria), Abbasi R. (Austria), Frech C. (Austria), Ziegler A.(Austria), Westermann F. (Germany), Ambros I.M. (Austria), Ambros P.F. (Austria)

16h50 PD-L1-expressing circulating breast cancer cells: Correlation with tissue expression and clinical evolution
Jacot W. (France), Mazel M. (France), Mollevi C. (France), Pouderoux S. (France), D'Hondt V. (France), Cayrefourcq L. (France), Ducteil A. (France), Viala M. (France), Maudelonde T. (France), Guiu S. (France), Alix Panabieres C. (France)

17h05 RANK expression in Circulating Tumor Cells (CTCs): clinical utility in monitoring metastatic Breast cancer patients (MBC) under Denosumab treatment
Zamarchi R. (Italy), Facchinetti A. (Italy), Rossi E. (Italy), Zoccoli A. (Italy), Iuliani M. (Italy), Pantano F. (Italy), Bruno V. (Italy), Tonini G. (Italy), Santini D. (Italy)

17h20 Microsatellite instability detection in circulating blood DNA by droplet-digital PCR
Silveira A. (France), Bidard F.C. (France), Bieche I. (France), Melaabi S. (France), Cabel L. (France), Buecher B. (France), Pierga J.Y. (France), Stern M.H. (France), Proudhon C. (France)

17h35 The novel detection of the EGFR-T790M mutation in exhaled breath condensate
Smyth R. (Ireland), Toomey S. (Ireland), Sartori A. (Germany), O'Hanrahan E. (Ireland), Cuffe S. (Ireland), Breathnach O. (Ireland), Morgan R. (Ireland), Hennessy B. (Ireland)

17h50 Visualisation and quantification of AR-V7, AR-FL, PSA and KRAS point mutations in CTCs
El-Heliebi A. (Austria), Hille C. (Germany), Laxman N. (Sweden), Svedlund J. (Sweden), Haudum C. (Austria), Ercan E. (Austria), Kroneis T. (Austria), Chen S. (Austria), Smolle M. (Austria), Rossmann C. (Austria), Krzywkowski T. (Sweden), Ahlford A. (Sweden), Darai E. (Sweden), von Amsberg G. (Germany), Winfried A. (Germany), König F. (Germany), Löhr M. (Sweden), de Kruijff I. (The Netherlands), Riethdorf S. (Germany), M. Gorges T. (Germany), Pantel K. (Germany), Bauernhofer T. (Österreich), Nilsson M. (Sweden), Sedlmayr P. (Austria)

18h05 Change in circulating microRNA expression during neoadjuvant chemoradiation for rectal cancer
Spring K. (Australia)

SESSION 6
Biology of tumor cell dissemination and metastasis
Chairmen: David Azria (France), Bruce Zetter (USA)

08h30 Keynote Lecture: Latency, Immune Evasion, and Outbreak of Metastatic Stem Cells
Joan Massagué (USA)

09h00 Stromal niches for bone metastasis
Yibin Kang (USA)

09h25 Targeting Aggressive Cancers
Bruce Zetter (USA)

09h50-10h20 // Coffee Break & Visit of the Exhibition

10h20 Targeting tumor dormancy to prevent breast cancer recurrence
Lewis Chodosh (USA)

10h45 A new role for VEGF-C in metastatic conditioning of the lung
Jonathan Sleeman (Germany)

SESSION 7
Circulating tumor cells (I/II)
Chairpersons: Paola Gazzaniga (Italy), Dan Hayes (USA)

11h10 Functional analyses of CTCs in cancer patients
Catherine Alix-Panabières (France)

11h35 Gene expression and DNA methylation analysis in circulating tumor cells
Evi Lianidou. (Greece)

12h00 USP7 targeting identifies a metastasis-competent state within BM-resident melanoma CTCs
Dario Marchetti (USA)

12h25-13h35 // Lunch Break & Visit of the Exhibition

SESSION 7
Circulating tumor cells (II/II)
Chairpersons: Paola Gazzaniga (Italy), Dan Hayes (USA)

13h35 Advancing CTC-based liquid biopsies
Nick Stoecklein (Germany)

14h00 CTC Isolation Methods and Clinical Treatment Monitoring
Hugh Fan (USA)

14h25 Circulating Tumor Cells, what have we learned
Leon Terstappen (The Netherlands)

14h50 Patient-derived models: opportunities, challenges, and newer tools for exploring the biology of metastasis
Stefanie Jeffrey (USA)

15h15-15h45 // Coffee Break & Visit of the Exhibition

SESSION 8
Circulating cell-free tumor DNA and exosomes
Chairmen: Klaus Pantel (Germany) , Michael Speicher (Austria)

15h45 Keynote Lecture: Towards Cancer Screening Using Circulating DNA
Dennis Lo (Hong Kong)

16h15 Cell-free DNA for minimal residual disease analysis
Luis Diaz (USA)

16h40 The impact of circulating tumor DNA analyses on precision oncology
Michael Speicher (Austria)

17h05 ctDNA in breast cancer
Carlos Caldas (UK)

17h30 Utility of new cfna approaches for assessment of cancer progression
Dave Hoon (USA)

17h55 Nanosized particles promote systemic effects of cancer
David Lyden (USA)

18h20 Developing Exosomes Based Platform for Diagnosis and Treatment of Cancer
Raghu Kalluri (USA)

20h00 **GALA DINNER**

SESSION 9
CTCs as liquid biopsy in clinical studies
Chairpersons: Stefanie Jeffrey (USA), William Jacot (France)

08h30 Vasculogenic Mimicry as a mechanism for dissemination and metastasis in SCLC
Caroline Dive (UK)

08h55 Liquid biopsy as a potential tool for using predictive biomarkers in immunotherapy
Paul Hofman (France)

09h20 Insight into CTC diversity through single-cell analysis and CDX development
Françoise Farace (France)

09h45 Circulating Tumor Cells as a Prognostic Factor in Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: CIRCUTEC study
Renaud Garrel (France)

10h10 Circulating tumor cells as prognostic and predictive factor in metastatic colo-rectal cancer : results of COLOSPOT study
Thibaut Mazard (France)

10h35-11h05 // Coffee Break & Visit of the Exhibition

11h05 CTC Phenotyping and Genotyping in Breast Cancer - an Update - KEYNOTE
Daniel Hayes (USA)

11h35 Clinical utility of CTC and ctDNA in metastatic and neo/adjuvant setting of breast cancer
Jean-Yves Pierga (France)

12h00 Clinical Utility of Circulating Tumor Cells in Advanced Breast Cancer – the Detect-Study Program
Thomas Friedl (Germany)

12h25 Liquid Biopsies: A Path to Clinical Utility
Howard Scher (USA)

12h50 Interrogating the AR in Advanced Prostate Cancer Using Liquid Biopsies
Emmanuel Antonarakis (USA)

13h15-14h25 // Lunch Break, & Visit of the Exhibition

SESSION 10
Emerging commercial technologies
Chairmen: Leon Terstappen (The Netherlands), Hugh Fan (USA)

14h25 A robust method to study cancer heterogeneity in liquid biopsy
Nicolò Manaresi Phd, Chief Scientific Officer MENARINI SILICON BIOSYSTEMS

14h45 Advancing Liquid Biopsy with Next Generation Sequencing
Kelli Bramlett, Director, R&D Clinical Next Generation Sequencing Division Life Sciences Solution, THERMO FISHER SCIENTIFIC

15h00 Sensitivity matters – Comparison of different methods for Liquid Biopsy testing
Pierre-Jean Lamy, Dr. , AGENA BIOSCIENCE

SESSION 3
Immune system and cancer (II/II)
Chairman: Paul Hofman

15h15 The immune contexture of tumors : a novel view on cancer evolution
Jérôme Galon (France)

15h40-16h10 // Coffee Break & Visit of the Exhibition

SESSION 11
Circulating cell-free miRNA and platelets
Chairpersons: Tom Würdinger (The Netherlands), Catherine Alix-Panabières (France)

16h10 Tumor-educated platelets for the detection of cancer
Tom Würdinger (The Netherlands)

16h35 About Chomsky, patterns and cell to cell communication by non-coding RNAs
George Calin (USA)

17h00 **Closing Remarks with Poster Awards and Travel Awards**
supported by MDPI *supported by JANSSEN*

14h35 - 15h20
Session 4: Poster Sessions 1 (in the Exhibition area)

» BIOLOGY OF TUMOR CELL DISSEMINATION AND METASTASIS

P-1
Genomic analysis of bone marrow-derived disseminated neuroblastoma cells to identify relapse-seeding clone
Abbasi R. (Austria), Rifatbegovic F. (Austria), Brunner C. (Austria), Mann G. (Austria), Ziegler A. (Austria), Pötschger U. (Austria), Crazzolara R. (Austria), Ussowicz M. (Poland), Benesch M. (Austria), Ebetsberger-Dachs G. (Austria), Chan G.C. (Hong Kong), Jones N. (Austria), Ladenstein R. (Austria), Ambros I.M. (Austria), Ambros P.F. (Austria)

P-2
Up-regulation of flotillins, new marker of metastatic development, induces an epithelial to mesenchymal transition
Genest M. (France), Planchon D. (France), Comunale F. (France), Seveno M. (France), Gauthier-Rouvière C. (France), Bodin S. (France)

P-3
Droplet Microfluidic Platform for Single-Cell RT-qPCR Analysis
Hajji I. (France), Serra M. (France), Geremie L. (France), Renault R. (France), Viovy J.L. (France), Descroix S. (France), Ferraro D. (France)

P-4
Prognostic value of disseminated tumor cells in patients with luminal breast cancer
Irina D. (Russian Federation), Ryabchikov D. (Russian Federation), Beznos O. (Russian Federation), Vorotnikov I. (Russian Federation), Chkhikvadze N. (Russian Federation), Denchik D. (Russian Federation), Tupitsyn N. (Russian Federation)

P-5
HER2 activation by FHIT downregulation in lung tumor cells
Da Silva J. (France), Jouida A. (France), Bonnomet A. (France), Birembaut P. (France), Dalstein V. (France), Polette M. (France), Nawrocki-Raby B. (France)

P-6
Testing a label-free CTC-enrichment method to isolate viable pancreatic cancer CTC
Guglielmi R. (Germany), Neves R.P.L. (Germany), Raba K. (Germany), Stoecklein N.H. (Germany)

P-7
Xenotransplantation of human cancer cells in the zebrafish: a tool to study an in-vivo metastasis process
Lounici Y. (France), Bureau C. (France), Fontenille L. (France), Kissa K. (France)

P-8
Characterization of Diffuse Low Grade Gliomas in vitro
Augustus M. (France), Leventoux N. (France), Rigau V. (France), Duffau H. (France), Hugnot J.P. (France)

P-9
European Liquid Biopsies Academy (ELBA) - Towards widespread clinical application of blood-based diagnostic tools
Koppers-Lalic D. (Netherlands), Wurdinger T. (Netherlands), Pantel K. (Germany), Rosell R. (Spain), Lyden D. (Usa), Alix Panabieres C. (France), Baev V. (Bulgaria), Hackenberg M. (Spain), Fernandez Hilario A. (Spain), Karachaliou N. (Spain), Zarovni N. (Italy)

P-10
The importance of circulating tumor cells and circulating sphere forming cells in the course of disease in patients with malignant solid tumors
Lux D. (Germany)

P-11
Identification and monitoring of a high-level MET amplification in CTCs and cfTNA in an ALK-rearranged NSCLC patient treated with crizotinib, alectinib and ceritinib
Berger L.A. (Germany), Velthaus J.L. (Germany), Janning M. (Germany), Schatz S. (Germany), Falk M. (Germany), Iglauer P. (Germany), Simon R. (Germany), Cao R. (Usa), Bramlett K. (Usa), Buson G. (Italy), Petrini E. (Italien), Forcato C. (Italie), Tiemann M. (Germany), Sauter G. (Germany), Bokemeyer C. (Germany), Reck M. (Germany), Riethdorf S. (Germany), Pantel K. (Germany), Wikman H. (Germany), Loges S. (Germany)

P-118
Locally Ablative Radiation Therapy of Human Small Cell Lung Cancer Decreases the Number of Spontaneous Metastases in Xenograft Models
Frenzel T. (Germany), Siekman J. (Germany), Grohmann C. (Germany), Valentiner U. (Germany), Schmitz R. (Germany), Riecken K. (Germany), Fehse B. (Germany), Schumacher U. (Germany), Krüll A. (Germany), Lange T. (Germany)

» CIRCULATING CELL-FREE TUMOR DNA

P-12
CircSarc; A non-invasive insight into the sarcoma genome
Namløs H.M. (Norway), Boye K. (Norway), Moosavi S.H. (Norway), Mishkin S. (Usa), Samarakon P. (Norway), Lorenz S. (Norway), Barøy T. (Norway), Bjerkehagen B. (Norway), Granlien S. (Norway), Næss S. (Norway), Zaikova O. (Norway), Stratford E. (Norway), Munthe E. (Norway), Aasheim L.B. (Norway), Hovig E. (Norway), Jebsen N. (Norway), Kudlow B. (Usa), Myklebost O. (Norway), Meza-Zepeda L.A. (Norway)

P-13
HPV circulating tumor DNA to monitor the efficacy of chemoradiotherapy in non-metastatic anal carcinoma
Bernard A. (France), Cabel L. (France), Jeannot E. (France), Bieche I. (France), Vacher S. (France), Callens C. (France), Morel A. (France), Lièvre A. (France), Otz J. (France), Minsat M. (France), Pierga J.Y. (France), Buecher B. (France), Mariani P. (France), Bidard F.C. (France), Cacheux W. (France)

P-14
Evaluation of a new multiplex assay using droplet digital PCR for tracking sensitive and resistant mutations in ctDNA : comparison with Cobas and NGS
Denis J.A. (France), Guillerm E. (France), Henaff D. (France), Gobert A. (France), Lamy P.J. (France), Lacorte J.M. (France), Coulet F. (France), Fina F. (France)

P-15
Role of frequent chr13 q12.2 amplification in colorectal cancer patients
Zhou Q. (Österreich), Perakis S. (Austria), Ulz P. (Österreich), Pichler M. (Österreich), Gerger A. (Österreich), Bauernhofer T. (Österreich), Geigl J.B. (Austria), Heitzer E. (Austria), Speicher M.R. (Österreich)

P-16
Non-invasive genotyping of locally advanced rectal cancer patients using circulating tumour DNA
Toomey S. (Ireland), Sartori A. (Germany), Irwin D. (Australia), Carr A. (Ireland), Armstrong P. (Ireland), Farrelly A. (Ireland), O'Sullivan L. (Ireland), Bradshaw S. (Ireland), Smyth R. (Ireland), Workman J. (Ireland), Lee C.L. (Ireland), O'Neill B. (Ireland), Hennessy B. (Ireland)

P-17
Single-stranded library preparation does not preferentially enrich circulating tumor DNA
Moser T. (Austria), Ulz P. (Austria), Zhou Q. (Austria), Perakis S. (Austria), Geigl J.B. (Austria), Speicher M.R. (Austria), Heitzer E. (Austria)

P-18
Comparison study of manual and automated extraction systems for cell-free circulating DNA
Ockhardt A. (Deutschland), Shaw J. (Vereinigtes Königreich), Cowley C. (Vereinigtes Königreich), Joos H. (Germany)

P-19
Automation of Real-Time Quantitative PCR based Minimal Residual Disease Monitoring by Centrifugal Microfluidics
Juelg P. (Germany), Kipf E. (Deutschland), Eckert C. (Deutschland), Paust N. (Deutschland), Zengerle R. (Deutschland), Hutzenlaub T. (Deutschland)

P-20
Pre-analytical aspects of extracted circulating cell-free DNA: impact of storage conditions and exposure to freeze-thawing.
Qvick A. (Sweden), Helenius G. (Sweden)

P-21
Concordance of genomic mutations in tissue vs circulating tumour DNA (ctDNA) in metastatic melanoma
Calapre L. (Australia), Giardina T. (Australia), Robinson C. (Australia), Reid A. (Australia), Al-Ogaili Z. (Australia), Pereira M. (Australia), Mcavoy A. (Australia), Warburton L. (Australia), Khattak M.A. (Australia), Meniawy T. (Australia), Millward M. (Australia), Amanuel B. (Australia), Ziman M. (Australia), Gray E. (Australia)

P-22
Circulating tumor DNA to personalize treatment in patients with RAS mutant metastatic colorectal cancer
Paola G. (Italy), Loreni F. (Italy), Raimondi C. (Italy), Chiara N. (Italy), Angela G. (Italy), Federica U. (Italy), Enrico C. (Italy)

P-23
DNA methylation analysis in liquid biopsy: a detailed study on quality control, sample storage and whole genome amplification procedures for downstream applications.
Mastoraki S. (Greece), Chimonidou M. (Greece), Tzanikou E. (Greece), Lianidou E. (Greece)

P-24
Activating ESR1 mutations detection by single ddPCR assay
Proudhon C. (France), Jeannot E. (France), Bidard F.C. (France), Cabel L. (France), Epaillard N. (France), El Ayachi R. (France), Noret A. (France), Vincent-Salomon A. (France), Pierga J.Y. (France), Bieche I. (France), Stern M.H. (France)

P-25
Development of a fully automated microfluidic magnetic fluidized bed for circulating tumor DNA detection
Alexandre L. (France), Perez K. (France), Viovy J.L. (France), Descroix S. (France), Malaquin L. (France)

P-26
Patient-Specific Circulating Tumor DNA Detection during Palbociclib/Fulvestrant therapy in HR+/HER2- Metastatic Breast Cancer.
Darrigues L. (France), Proudhon C. (France), Bidard F.C. (France)

P-27
Mutation analysis in liquid biopsies and tissue segments of lung adenocarcinoma patients
Dietz S. (Germany), Riediger A.L. (Germany), Kazdal D. (Germany), Harms A. (Germany), Stenzinger A. (Germany), Warth A. (Germany), Schneider M. (Germany), Meister M. (Germany), Muley T. (Germany), Thomas M. (Germany), Sültmann H. (Germany)

P-30
TruePrime Liquid Biopsy: the first tool to amplify cell-free DNA
Picher Á. (Spain), Juárez R. (Spain), Budeus B. (Germany)

P-31
Application of the Highly Sensitive SiMSen-Seq Assay and Seraseq Designed Reference Materials to Minimal Residual Disease Detection
Garlick R. (United States), Konigshofer Y. (United States), Butler M. (United States), Egyud M. (United States), Stahlberg A. (Sweden), Godfrey T. (United States)

P-32
LIQBIOPSENS: A Novel, Reliable and Affordable Platform for Colorectal Cancer Patients Screening (H2020-IA 687785)
Garrido Navas M.D.C. (Spain), Robles Remacho A. (Spain), Delgado Ureña M. (España), González Flores E. (España), López Castro R. (España), Illyne H. (Reino Unido), Díaz Mochon J. (España), Serrano M.J. (España)

P-33
Circulating cell free tumor DNA: dynamics in patients with advanced and localized cancer disease
Hilke F.J. (Germany), Zwirner K. (Deutschland), Bitzer M. (Deutschland), Malek N. (Deutschland), Kootz B. (Deutschland), Stephan O. (Deutschland), Gani C. (Deutschland), Riess O. (Deutschland), Zips D. (Deutschland), Welz S. (Deutschland), Christopher S. (Deutschland)

P-34
Analysis of cell free tumor DNA for the treatment monitoring in two patients with advanced melanoma.
Hilke F.J. (Germany), Müller A. (Deutschland), Hahn M. (Deutschland), Klumpp B. (Deutschland), Sonja H. (Deutschland), Eigentler T. (Deutschland), Sinnberg T. (Deutschland), Niessner H. (Deutschland), Riess O. (Deutschland), Garbe C. (Deutschland), Röcken M. (Deutschland), Forschner A. (Deutschland), Schroeder C. (Deutschland)

P-35
ThermoFisher NGS Assay for Low Frequency 0.01% Analyte Detection
Bramlett K. (Usa), Cao R. (Usa), Hanif K. (United States)

P-36
Verification of a complete Sample to Insight® liquid biopsy workflow - NGS of ccfDNA from stabilized blood
Ullius A. (Germany), Krenz T. (Germany), Sprenger-Haussels M. (Germany), Hübel R. (Germany), Voss T. (Germany), Provencher E. (United States), Buirkle T. (United States), Groelz D. (Germany)

P-37
Detection of tumor-associated gene mutations in cell-free DNA of early-stage non-small cell lung cancer patients
Kimura H. (Japan), Koba H. (Japan), Kasahara K. (Japan)

P-38
Evaluation of complete and quantitative size distribution of cfDNA as a monitoring marker in oncology.
Taly V. (France), Wang-Renault S. (France), Garrigou S. (France), Boutonnet-Rodat A. (France), Carrillon M.J. (France), Pacelli J. (France), Pietraz D. (France), Didelot A. (France), Bats A.S. (France), Bachet J.B. (France), Blons H. (France), Zaanan A. (France), Ginot F. (France), Laurent-Puig P. (France)

P-39
Cell free DNA in radiation oncology: a beneficial biomarker to distinguish toxicity from infection?
Zwirner K. (Germany), Hilke F.J. (Germany), Demidov G. (Deutschland), Ossowski S. (Deutschland), Gani C. (Deutschland), Rieß O. (Deutschland), Zips D. (Deutschland), Welz S. (Deutschland), Schroeder C. (Deutschland)

P-119
Clinical implication of ctDNA analysis in advanced lung carcinoma patients using two different technologies: real-time PCR and MALDI-TOF
Lamy P.J. (France), Zornbach K. (Germany)

» CIRCULATING TUMOR CELLS

P-40
Deep Learning to identify Circulating Tumor Cells by ACCEPT
Zeune L. (Netherlands), Van Dalum G. (Germany), Nanou A. (Netherlands), de Wit S. (Netherlands), Andree K. (Netherlands), Swennenhuis J. (Netherlands), Terstappen L. (Netherlands), Brune C. (Netherlands)

P-41
Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients - results from the adjuvant SUCCESS A trial
Marie T. (Germany), Rack B. (Germany), Schneeweiss A. (Germany), Müller V. (Germany), Fehm T. (Germany), Gade J. (Germany), Lorenz R. (Germany), Rezai M. (Germany), Tesch H. (Germany), Polasik A. (Germany), Schochter F. (Germany), de Gregorio A. (Germany), Ernst K. (Germany), Bekes I. (Germany), Mahner S. (Germany), Schindlbeck C. (Germany), Beckmann M.W. (Germany), Fasching P.A. (Germany), Janni W. (Germany), Friedl T.W.P. (Germany)

P-42
The tumor-initiating capacity of prostate circulating tumor cells examined through a unique CTC-derived eXplant (CDX) model
Faugeroux V. (France), Pailler E. (France), Deas O. (France), Brulle-Soumare L. (France), Marty V. (France), Alexandrova K. (France), Andree K. (Netherlands), Scoazec J.Y. (France), Stoecklein N. (Germany), Tramalloni D. (France), Ngocamus M. (France), Nicotra C. (France), Terstappen L. (The Netherlands), Lapierre V. (France), Fizazi K. (France), Loriot Y. (France), Judde J.G. (France), Farace F. (France)

P-43
Autologous cell lines established from circulating colon cancer cells captured at sequential liquid biopsies: a tool to investigate therapy-driven evolution of metastatic disease?
Soler A. (France), Cayrefourcq L. (France), Mazard T. (France), Babayan A. (Germany), Lamy P.J. (France), Pantel K. (Germany), Assou S. (France), Assenat E. (France), Alix Panabieres C. (France)

P-44
Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases - Implications as a Marker for Oligo-metastatic Disease
Wikman H. (Germany), Hanssen A. (Germany), Riebensahm C. (Germany), Mohme M. (Germany), Joosse S. (Germany), Lamszus K. (Germany), Loges S. (Germany), Westphal M. (Germany), Riethdorf S. (Germany), Pantel K. (Germany)

P-45
Circulating tumor cell assessment in the management of advanced melanoma patients
Lucci A. (United States), Hall C. (United States), Ross M. (United States), Bowman Bauldry J. (United States), Royal R. (United States), Upshaw J. (United States)

» CTCS AS LIQUID BIOPSY IN CLINICAL STUDIES

P-46
Protocol optimization for mass cytometry analysis of circulating tumor cells subpopulations
Rodriguez-Martinez A. (Spain), Puche-Sanz I. (Spain), Robles-Fernández I. (Spain), Garrido C. (Spain), Cózar Olmo J.M. (Spain), Lorente Acosta J.A. (Spain), Serrano Fernández M.J. (Spain)

P-47
Circulating tumor cells are a strong predictor of cancer specific survival in high risk non-muscle invasive bladder cancer: final analysis of a prospective observational study
Paola G. (Italy), Gradilone A. (Italy), Chiara N. (Italy), Cristina R. (Italy), Flavia L. (Italy), Nicole C. (Italy), Ettore D.B. (Italy), Isabella S. (Italy), Enrico C. (Italy)

P-48
Ultra-high sensitive and quantitative measurement of the Prostate Specific Antigen (PSA) expressed by the Circulating Tumor Cells (CTCs) with the SIMOA immunoassay technology.
Seigneres B. (France), Bastide M.C. (France), Rebillard X. (France), Poinas G. (France), Cayrefourcq L. (France), Alix Panabieres C. (France)

P-49
MicroRNA profile of cell lines from CTCs in colon cancer
Cayrefourcq L. (France), Alix Panabieres C. (France), Assou S. (France)

P-50
Comparative analysis of Circulating Tumour Cells detection and circulating tumor DNA in liquid biopsy for the diagnosis of early stage pancreatic adenocarcinoma
Buscail E. (France), Caumont C. (France), Alix Panabieres C. (France), Quincy P. (France), Degrandi O. (France), Marty M. (France), Merlio J.P. (France), Bedel A. (France), Moreau-Gaudry F. (France), Vendrely V. (France), Laurent C. (France), Dabernat S. (France), Chiche L. (France)

P-51
Circulating tumor cells correlate to response of immune modulating therapy in non-small cell lung cancer patients
Tamminga M. (Netherlands), de Wit S. (Netherlands), Hilterman J. (Nederland), Schuuring E. (Netherlands), Terstappen L. (Netherlands), Groen H. (Nederland)

P-53
Automated detection of CTCs/CTMs after size-based selection from blood of patients with melanoma
Soussaline F. (France), Groult J. (France), Homsy C. (France), Tatarinova E. (France), Da-Meda L. (France), Benali-Furet N. (France), Ye F. (France), Papine A. (France), Uzan G. (France), Lebbé C. (France), Wechsler J. (France)

P-54
In vivo isolation of circulating tumor cells in different clinical settings for multiple downstream applications
Jurinke C. (Germany), Osanto S. (Netherlands), Gallerani G. (Italia), Fabbri F. (Italy)

P-55
ERA-NET-action: PROLIPSY - Early Detection of Prostate Cancer by Liquid Biopsies
Werner S. (Germany), Zabel M. (Poland), Lianidou E. (Greece), Bonci D. (Italy), Alix Panabieres C. (France), Pantel K. (Germany)

P-56
PD-L1 expression on circulating epithelial tumor cells (CETCs) is associated with immune evasion and tumor progression in breast cancer patients and differs from PD-L2 expression
Lux D. (Germany)

P-57
Circulating Tumor Cell Monitoring Did Not Predict Response To Pelvic-Directed Neoadjuvant Therapy
You Y. (United States), Hall C. (United States), Chang G.J. (United States), Bednarski B. (United States), Lee L. (United States), Cuddy A. (United States), Rodriguez-Bigas M. (United States), Messick C.A. (United States), Nickerson P. (United States), Skibber J.M. (United States), Lucci A. (United States)

P-58
Hyaluronidase treatment reveals a different gene expression profile of circulating tumor cells enriched with antibody based methods in prostate cancer patients.
Josefsson A. (Sweden), Larsson K. (Sweden), Damber J.E. (Sweden), Kubista M. (Sweden), Welén K. (Sweden)

15h20 - 16h05
Session 4: Poster Sessions 2 (in the Exhibition area)

» IMMUNE SYSTEM AND CANCER

P-59
ZO-1: a factor able to recruit inflammatory cells in lung cancer
Neyrinck-Leglantier D. (France), Lesage J. (France), Nawrocki-Raby B. (France), Bonnomet A. (France), Blacher S. (Belgique), Birembaut P. (France), Gilles C. (Belgium), Polette M. (France)

P-61
Oncogenic Kras control of pancreas tumor immunity
Lebleu V. (United States), Rodriges Blanko E. (United States)

» CANCER CELL STEMNESS AND EPITHELIAL-MESENCHYMAL PLASTICITY

P-63
Quantifying epithelial-mesenchymal plasticity and its association with patient survival
Jolly M.K. (United States), George J. (United States), Jia D. (United States), Tripathi S.C. (United States), Xu S. (United States), Somarelli J.A. (United States), Hanash S. (United States), Levine H. (United States)

P-64
Notch pathway inhibition abolish the resistance to TKIs conferred by EGFR gatekeeper mutations
Maraver A. (France), Bousquet E. (France)

» CIRCULATING CELL-FREE MIRNA, EXOSOMES, PLATELETS

P-65
Are extracellular vesicles able to control human pluripotent stem cell fate?
Buscail E. (France), Quincy P. (France), Gounou C. (France), Raymond A.A. (France), Lamrissi-Garcia I. (France), Moranvillier I. (France), Saltel F. (France), Moreau-Gaudry F. (France), Brisson A. (France), Bedel A. (France), Dabernat S. (France)

P-67
Evaluation of miRNA extraction technologies in a multicentric manner - relevance for a standardized clinically-relevant miRNA analysis workflow
Neumann M. (Germany), Di Pasquale F. (Germany), Shaffer J. (United States), Sprenger-Haussels M. (Germany), Schlumpberger M. (Germany), Ammerlaan W. (Luxembourg), Betsou F. (Luxembourg), Af Hällström T. (Finland), Lianidou E. (Greece), Sjöback R. (Sweden), Bender S. (Germany), Schlange T. (Germany)

P-68
MicroRNA Expression profiling in Saliva from patients with Colorectal Cancer
Rapado-González Ó. (Spain), Majem B. (Spain), Díaz-Peña R. (Spain), Abalo A. (Spain), Álvarez-Castro A. (Spain), Suarez-Cabrera L. (Spain), Muinelo-Romay L. (Spain), Gil-Moreno A. (Spain), Santamaría A. (Spain), López-López R. (Spain), Suárez-Cunqueiro M.M. (Spain)

P-69
Cell Free miRNA2110 is Negatively Regulated by ZEB2
Balcik Ercin P. (Turkey), Yalim-Camci I. (Türkiye), Cetin M. (Türkiye), Odabas G. (Türkiye), Aysan A. (Türkiye), Yagci T. (Türkiye)

P-70
Evidence that circulating proteins are more promising than miRNAs for identification of patients with squamous cell carcinoma of the tongue
Boldrup L. (Sweden)

» CIRCULATING TUMOR CELLS

P-73
Analysis of single circulating tumor cells (CTCs) identifies resistance mutations to ALK-inhibitor in both ALK-gene and bypass oncogenic pathways
Pailler E. (France), Faugeroux V. (France), Oulhen M. (France), Queffelec P. (France), Forcato C. (Italie), Honoré A. (France), Laporte M. (France), Lecluse Y. (France), Lacroix L. (France), Marty V. (France), Ngocamus M. (France), Nicotra C. (France), Remon J. (France), Mezquita L. (France), Planchard D. (France), Soria J.C. (France), Manaresi N. (Italie), Besse B. (France), Farace F. (France)

P-74
Persistence of circulating tumor cells in high-risk early breast cancer patients during follow-up care suggests poor prognosis - Results from the adjuvant SUCCESS A trial
de Gregorio A. (Germany), Rack B. (Germany), Fasching P.A. (Germany), Häberle L. (Germany), Friedl T.W.P. (Germany), Tesch H. (Germany), Lorenz R. (Germany), Tzschaschel M. (Germany), Fehm T. (Germany), Müller V. (Germany), Schneeweiss A. (Germany), Lichtenegger W. (Germany), Beckmann M.W. (Germany), Schochter F. (Germany), Scholz C. (Germany), Pantel K. (Germany), Janni W. (Germany)

P-75
Circulating tumor cells in the peripheral blood and leukapheresis product of non-small cell lung cancer patients
Andree K. (Netherlands), Tamminga M. (Nederland), Mentink A. (Nederland), Hilterman J. (Nederland), Groen H. (Nederland), Terstappen L. (Nederland)

P-76
Circulating Tumour Cells as a biomarker of early/recurrent disease and therapeutic response in a preclinical model of osteosarcoma
Heymann D. (France), Chalopin A. (France), Tellez-Gabriel M. (Spain), Brown H.K. (United Kingdom), Heymann M.F. (France), Gouin F. (France)

P-77
Gene expression profile of autologous cell lines established from colon circulating tumor cells captured at sequential liquid biopsies
Cayrefourcq L. (France), Assou S. (France), Alix Panabieres C. (France)

P-78
Single-cell genetic analysis helps to validate cytopathological identification of Circulating Cancer Cells in patients with Clear Cells Renal Cell Carcinoma.
Broncy L. (France), Ben Njima B. (Tunisia), Méjean A. (France), Béroud C. (France), Ben Romdhane K. (Tunisia), Ilie M. (France), Hofman V. (France), Muret J. (France), Hofman P. (France), Chaabouni Bouhamed H. (Tunisia), Paterlini-Brechot P. (France)

P-79
Detection of activating and resistance mutations in single CTCs from EGFR-mutant non-small cell lung cancer patients treated by EGFR inhibitors
Oulhen M. (France), Aberlenc A. (France), Pailler E. (France), Faugeroux V. (France), Mezquita L. (France), Honoré A. (France), Remon J. (France), Lacroix L. (France), Lecluse Y. (France), Manaresi N. (Italie), Ngocamus M. (France), Nicotra C. (France), Planchard D. (France), Soria J.C. (France), Besse B. (France), Farace F. (France)

P-80
Fluorescence in situ hybridization analysis in CTCs of non-small cell lung cancer patients isolated with the PARSORTIX platform
Ntzifa A. (Greece), Zavridou M. (Greece), Pollakis P. (Greece), Bardi G. (Greece), Georgoulias V. (Greece), Kotsakis A. (Greece), Lianidou E. (Greece)

P-81
Development, analytical and clinical validation of a novel multiplex RT-qPCR assay for the simultaneous quantification of four AR splice variants (AR-FL, AR-V7, AR-567es and AR-total) in circulating tumor cells of mCRPC patients
Strati A. (Greece), Zavridou M. (Greece), Angelidis I. (Greece), Bournakis E. (Greece), Georgoulias V. (Greece), Lianidou E. (Greece)

P-82
Single cell profiling of Circulating Tumor Cells: Transcriptional intra-patient heterogeneity of endocrine resistant and phenotypic markers
Reinhardt F. (Germany), Franken A. (Germany), Meier-Stiegen F. (Germany), Driemel C. (Germany), Stoecklein N. (Germany), Fischer J. (Germany), Niederacher D. (Germany), Fehm T. (Germany), Neubauer H. (Germany)

P-84
Detecting Viable Circulating Tumour Cells Using Droplet Based Microfluidics
El Khoury M. (France), Eyer K. (France), Chenon G. (France), Cayrefourcq L. (France), Mazel M. (France), Bibette J. (France), Alix Panabieres C. (France), Baudry J. (France)

P-85
The rVAR2 malaria protein efficiently retrieves circulating tumor cells in a EpCAM-independent manner
Agerbæk M.Ø. (Denmark), Bang-Christensen S. (Denmark), Yang M.H. (Uk), Clausen T.M. (Denmark), Ditlev S.B. (Denmark), Pereira M.A. (Denmark), Nielsen M.A. (Denmark), Choudhary S. (Denmark), Gustavsson T. (Denmark), Sorensen P. (Canada), Meyer T. (Uk), Propper D. (Uk), Shamash J. (Uk), Theander T.G. (Denmark), Aicher A. (Uk), Daugaard M. (Canada), Heeschen C. (Uk), Salanti A. (Denmark)

P-86
Scanning Electron Microscopy of Circulating Tumor Cells and tumor-derived Extracellular Vesicles
Nanou A. (Netherlands), Flohr P. (United Kingdom), Crespo M. (United Kingdom), de Bono J. (United Kingdom), Terstappen L. (The Netherlands)

P-87
Decreasing number of circulating tumor cells in patients with urothelial carcinoma of the bladder undergoing preoperative chemotherapy and association with downstaging of the primary tumor after cystectomy: an interim analysis.
Abrahamsson J. (Sweden), Sjödahl G. (Sweden), Löfgren A. (Sweden), Sörenby A. (Sweden), Ståhl O. (Sweden), Cwikiel M. (Sweden), Aaltonen K. (Sweden), Rydén L. (Sweden), Liedberg F. (Sweden)

P-88
A 3D microdevice for the in vivo trapping of cancer-associated circulating cells
Jimenez Zenteno A.K. (France), Esteve A. (France), Bou E. (France), Blatché C. (France), Vieu C. (France), Malavaud B. (France), Cerf A. (France)

P-89
The genetic heterogeneity and the molecular evolution of systemic metastatic castration resistant prostate cancer during therapy
Lousa Das Neves R.P. (Germany), Streit A. (Deutschland), Raba K. (Germany), Bongers E.K. (Deutschland), Behrens B. (Germany), Flohr P. (United Kingdom), Mateo J. (Vereinigtes Königreich), Sumanasuriya S. (Vereinigtes Königreich), Crespo M. (United Kingdom), Ebbs B. (Vereinigtes Königreich), Fowler G. (Vereinigtes Königreich), Carreira S. (Vereinigtes Königreich), B. Lambros M. (Vereinigtes Königreich), Petrini E. (Italien), Garonzi M. (Italien), Manaresi N. (Italie), de Bono J. (United Kingdom), H. Stoecklein N. (Deutschland)

P-90
Breast cancer heterogeneity: genetics, estrogen receptor, metastasis, and treatment
Babayan A. (Germany), Prieske K. (Germany), Indenbirken D. (Germany), Alawi M. (Germany), Grundhoff A. (Germany), Müller V. (Germany), Pantel K. (Germany), Joosse S. (Germany)

P-91
Circulating Tumor Cells in Merkel Cell Carcinoma : Detection and MCPyV status
Boyer M. (France), Cayrefourcq L. (France), Foulongne V. (France), Dereure O. (France), Alix Panabieres C. (France)

P-92
Enrichment of paired EpCAM-high and EpCAM-low/negative CTCs within metastatic breast cancer blood samples and mutational analysis of the oncogene PIK3CA
Lampignano R. (Germany), Yang L. (Germany), Neumann M. (Germany), Franken A. (Germany), Fehm T. (Germany), Niederacher D. (Germany), Neubauer H. (Germany)

P-93
Androgen Receptor Expression in Circulating Tumor Cells of Patients with Metastatic Breast Cancer
Meier-Stiegen F. (Germany), Neubacher M. (Deutschland), Krawczyk N. (Deutschland), Neubauer H. (Germany), Janni W. (Germany), Fehm T. (Germany)

P-94
Digital droplet PCR test for detection of low abundant CTC captured on filters
Swennenhuis J.F. (Netherlands), de Wit S. (Netherlands), Terstappen L. (Netherlands)

P-95
Alpha-tubulin and detyrosinated tubulin in CTCs derived from non-small cell lung cancer (NSCLC) patients
Kallergi G. (Greece), Voumvouraki A. (Greece), Zacharopoulou N. (Greece), Stournaras C. (Greece), Martin S. (United States), Georgoulias V. (Greece)

P-96
The prognosis value of circulating tumour cells for localised prostate cancer
Lu Y.J. (United Kingdom), Xu L. (United Kingdom), Mao X. (United Kingdom), Guo T. (United Kingdom), Shaw G. (United Kingdom)

P-97
CTCs phenotypes and molecular analysis in esophageal cancer patients at the single cell level
Gallerani G. (Italia), Fici P. (Italia), Valgiusti M. (Italia), de Fanti S. (Italia), Frassineti G.L. (Italia), Bonafè M. (Italia)

P-98
PIM-1 expression in in-vivo isolated CTCs from high-risk prostate cancer patients
Markou A. (Ελλάδα), Tzanikou E. (Greece), Chen S. (Austria), Kroneis T. (Austria), Świerczewska M. (Poland), Budna J. (Poland), Kuske A. (Germany), Gorges T.M. (Germany), Zabel M. (Poland), Sedlmayr P. (Austria), Alix Panabieres C. (France), Pantel K. (Germany), Lianidou E. (Greece)

P-99
Development of a novel microfluidic CTC detection platform
Hille C. (Germany), Liu H.Y. (Germany), Horst L.J. (Germany), Babayan A. (Germany), Gorges T.M. (Germany), Haller A. (Austria), Hirtz M. (Germany), Fuchs H. (Germany), Pantel K. (Germany)

P-100
Cryopreserved CTCs Gained from DLA can be Used for In Vitro Culture
Franken A. (Germany), Driemel C. (Germany), Niederacher D. (Germany), Stoecklein N.H. (Germany), Fischer J. (Germany), Fehm T. (Germany), Neubauer H. (Germany)

P101
Gene expression analysis of circulating tumor cells in patients with head and neck squamous cell carcinoma; directed comparison of CTC-enrichment based on the EpCAM-independent PARSORTIX microfluidic device with EpCAM-based CTC isolation
Zavridou M. (Greece), Strati A. (Greece), Koutsodontis G. (Greece), Psyrri A. (Greece), Lianidou E. (Greece)

P-102
Evaluation of pre-analytical conditions for gene expression studies in CTCs
Zavridou M. (Greece), Strati A. (Greece), Lianidou E. (Greece)

P-103
Leukocyte depletion using ferrofluids to enrich circulating tumor cells from diagnostic leukapheresis
Terstappen L. (Netherlands), Mentink A. (Nederland), Andree K. (Netherlands), Brockhuis S. (Netherlands)

P-104
Self-Seeding Microwells to Isolate and Expand Single Cells
Andree K. (Netherlands), Abali F. (Nederland), Swennenhuis J. (Nederland), Passanha F. (Nederland), Oomens L. (Netherlands), Stevens M. (Nederland), Broekmaat J. (Netherlands), Terstappen L. (Nederland)

P-105
Post-Enrichment Melanoma Cell Isolation using the VyCap
Beasley A. (Australia), Oomens L. (Netherlands), Stevens M. (Netherlands), Tibbe A. (Netherlands), Broekmaat J. (Netherlands), Gray E. (Australia)

P-106
EGFR Mutational Detection in Vortex-enriched CTCs, ctDNA, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients
Sollier-Christen E. (United States), Liu H. (United States), Vuppalapaty M. (United States), Chiu M. (United States), Che J. (United States), Wilkerson C. (United States), Barzanian N. (United States), Crouse S. (United States), Carroll J. (United States), Matsumoto M. (United States), Di Carlo D. (United States), Garon E. (United States), Goldman J. (United States)

P-107
Detection of EGFR mutations into circulating tumor cells of patients with NSCLC by coupling cell-size based enrichment method and multiplex ddPCR
Denis J.A. (France), Benali-Furet N. (France), Guillerm E. (France), Gobert A. (France), Znaty A. (France), Uzan G. (France), Henaff D. (France), Fina F. (France), Coulet F. (France), Lacorte J.M. (France)

P-108
CTCs in Prostate Cancer: Molecular Characterization, Immunostaining and Counting by Combination of Label-free Parsortix CTC Enrichment and AdnaTest ProstateCancer Expression Profiling for PSA, PSMA, AR and AR-V7
O'Brien M. (United Kingdom), Van de Flierdt J. (Germany), Templeman A. (United Kingdom), Sprenger-Haussels M. (Germany), Mumford K. (United Kingdom), Hauch S. (Germany)

P-109
SIP-HAVA-seq as a tool to identify rare mutations and to measure DNA repair capacity in liquid biopsies
Cinquin O. (United States), Cinquin A. (United States), Taylor P. (United States)

P-110
A new workflow for monitoring and analysing circulating melanoma cells
Behrens B. (Germany), Bongers E.K. (Deutschland), Van Lierop A. (Germany), Neves R.P.L. (Germany), Guglielmi R. (Germany), Van Dalum G. (Germany), Wu J. (Germany), Wiesner U. (Germany), Knoefel W.T. (Germany), Homey B. (Germany), Stoecklein N.H. (Germany)

P-111
A workflow to evaluate PD-L1 protein expression on Circulating Tumor Cells (CTCs) from Non-Small Cell Lung Cancer (NSCLC).
Sollier-Christen E. (United States), Renier C. (United States), Wilkerson C. (United States), Hur S. (United States), Park D.E.R. (United States), Lemaire C. (United States), Matsumoto M. (United States), Carroll J. (United States), Crouse S. (United States), Goldman J. (United States), Garon E. (United States), Di Carlo D. (United States)

P-112
Comparison of cellsearch®, epispot and cellcollector ctc isolation techniques for early diagnostic in high-risk prostate cancer patients
Budna J. (Poland), Świerczewska M. (Poland), Cieślikowski W.A. (Poland), Mazel M. (France), Agnieszka J. (Poland), Agnieszka I. (Poland), Piotr Z. (Poland), Alix Panabieres C. (France), Andrzej A. (Poland), Maciej Z. (Poland)

P-113
Molecular characterization of negative enriched ctcs in metastatic breast and prostate cancer patients
Pereira Veiga T. (Spain), Martínez-Fernández M. (Spain), Abuin C. (Spain), López-López R. (Spain), Muinelo-Romay L. (Spain), Costa C. (Spain)

P-114
Caracterization and prognosis in triple negative breast cancer circulating tumor cells
Abreu Rodríguez M. (Spain), Cabezas P. (Spain), Abalo A. (Spain), Martinez N. (Spain), Varela V. (Spain), García P. (Spain), Sanchez L. (Spain), Lopez R. (Spain), Muinelo-Romay L. (Spain)

P-115
A 1-hour easy intracellular flow cytometry assay to detect Circulating Tumor Cells without pre-enrichment step
Lopresti A. (France), Malergue F. (France), Birnbaum D. (France), Acquaviva C. (France), Mamessier E. (France)

Sample to Insight:
Pioneering tools
for your cancer discoveries

Visit us at
Booth 9
Salon Esplanade
Level 3

Sample to Insight
QIAGEN

› Venue

The Corum Conference Center
Montpellier Downtown
Esplanade Charles De Gaulle - BP 2220 - 34000 Montpellier France
www.montpellier-events.com

Registration and Accommodation:
Do not forget to register for the congress and secure your accommodation on the following link: http://ismrc2018.com/en/registration/registration

	Early registration fees up to December 15th 2017	From December 16th 2017 up to April 15th 2018	After April 15th 2018
REGULAR	500,00€	600,00€	700,00€
GRADUATE STUDENT	280,00€	325,00€	375,00€
CANCER ID MEMBER	325,00€	375,00€	450,00€
INDUSTRY	700,00€	900,00€	1050,00€
GALA DINNER	85,00€	85,00€	85,00€

› How to get there?

Getting to the Corum from the airport

- Airport shuttle – line 120 – get off at the 'Place de l'Europe' (www.herault-transport.fr)
- Taxi call kiosk at airport - Tel.: +33 (0)4 67 20 65 29
- Méditerranée airport taxi group - Tel.: +33 (0)4 30 96 60 00
- Other Montpellier airport taxi group - Tel.: +33 (0)7 81 46 58 77
- Attractive discounts on a wide range of fares on all worldwide (coming soon)

Getting to the Corum from the train station

- Tram lines 2 and 4 (2 stops)
- 10 minutes' walk

Getting to the Corum by car

- Follow signs for Montpellier - Centre Historique - Le Corum
- Covered parking is available for a charge (500 places)
- Short stay pick up/drop off points are located on the west side of Le Corum (on the bus stop level).

› Contact

eventime

EVENTIME
44 bd. Périer - 13008 Marseille
Tel : +33 (0)4 91 94 54 72

REGISTRATION
Valérie ELMA
Tel : 33(0)4 67 61 66 65
Email : valerie.elma@eventime-group.com

ACCOMMODATION
Alexandra BOBAND
alexandra.boband@eventime-group.com
Tel: +33 4 91 94 30 38

SPONSORS AND PARTNERS
Djamila KERROUZI
Tel: +33 (0)4 91 94 54 72
Email: djamila.kerrouzi@eventime-group.com

SCIENTIFIC PROGRAMME, ABSTRACTS & SPEAKERS CONTACT
Christine HESSLER
Tel: +33 4 91 94 54 72
Email : christine.hessler@eventime-group.com

ETHICAL MEDTECH Evaluation - all lights are on GREEN!
The ISMRC 2018 has been evaluated and approved to be COMPLIANT.
Please find details on www.ethicalmedtech.eu

Exhibition Plan

May 3-5, 2018

Le Corum
MONTPELLIER, FRANCE



SOCIETE	ESPACE
AATI	12
AGENA Bioscience	8
ANGLE EUROPE LTD	10
AUTOMATED LAB SOLUTIONS Gmbh - ALS	22
AXLR SATT	20
BIO-RAD	14

SOCIETE	ESPACE
BIOVIEW Ltd.	5
CLEARBRIDGE BioMedics Pte Ltd	11
HTG MOLECULAR DIAGNOSTICS	3
ID SOLUTIONS	24
MENARINI SILICON BIOSYSTEMS	1
MERCK	18

SOCIETE	ESPACE
MILTENYI BIOTEC	16
NANOSTRING TECHNOLOGIES	17
SCREENCELL	7
STILLA TECHNOLOGIES	21
STRATEC Molecular GmbH	6
VORTEX	2

SOCIETE	ESPACE
VYCAP	23
QIAGEN	9
RARECELLS	4
ROCHE	19
THERMO FISHER SCIENTIFIC	15

› Sponsors 2018

We thank the Sponsors of the ISMRC Congress 2018 !

With the Support of La Région Occitanie Pyrénées · Méditerranée

// Diamond Sponsor:

MENARINI silicon biosystems

// Silver Sponsors:

Agena BIOSCIENCE · ANGLE · BIO-RAD · QIAGEN · ThermoFisher SCIENTIFIC

// Advert & Insert Sponsors:

Clearbridge BioMedics · nanoString · Rarecells DIAGNOSTICS · ScreenCell · STILLA

// Sponsors:

ADVANCED ANALYTICAL · ALS · axLR SATT · biaview · cancers · Cancéropole · HTG Molecular · sid solutions · janssen · MERCK · MACS Miltenyi Biotec · MUSE · Roche · stratec molecular · VyCAP

// Other Support:

AFU Association Française d'Urologie · BIODETECT · CANCER ID · CHU · EFLM · Eurobiomed · The European Liquid Biopsy Society · SIRIC Montpellier Cancer · Société de Biologie

› Notes

> Notes

Capture and harvest of Circulating Tumor Cells from blood*

ANGLE's Parsortix™ technology captures circulating tumor cells (CTCs) from blood*. The resulting "liquid biopsy" enables the genetic and protein analysis of the patient's cancer which has the potential to help direct optimal therapy – so moving towards personalised cancer care.



- Capture and harvest of CTCs from a wide range of cancers including lung, breast, prostate, colo-rectal, ovarian
- Antibody independent capture – including capture of mesenchymal cells and clusters of cells
- Simple operation with minimal user intervention
- Delivers viable cells ready for molecular and functional analysis
- Workflow allows the analysis of ctDNA and CTCs from the same patient sample

*Research use only – not for use in diagnostic procedures

For more information and latest publications please visit www.angleplc.com
or email parsortix@angleplc.com

ANGLE

DEPArray™ NxT

choose 100% purity

BREAKING THE BARRIER OF TUMOR HETEROGENEITY

Get conclusive data by selecting, sorting and collecting pure tumor and stromal cells to clearly assign genetic variant frequency. Achieving the ultimate level of purity is a necessary step to unambiguously resolve sample heterogeneity.

NEW FEATURES

High-resolution Imaging • 96 Recoveries • High-level Automation

Benchtop Instrument • D 2.23 ft x W 2.62 ft x H 2.02 ft

www.siliconbiosystems.com/deparray-nxt

For Research Use Only. Not for use in diagnostic procedures.

MENARINI silicon biosystems